TNF and atherosclerosis: Our observation linking TNF with progression suggests that sTNFR-1 can act as a marker of residual inflammatory risk, even in patients without evidence of overt atherosclerosis, and warrants further studies for selective inhibition of TNF and traditional CV risk reduction strategies (eg, lipid-lowering therapy) in patients with elevated sTNFR-1.